Nanobiotix is trading 5.6% up at $41.34 in pre-market, extending a sharp multi-month rebound driven by optimism around its cancer radioenhancer JNJ-1900 (NBTXR3).
- Recent Q1 2026 updates highlighted strong Phase 2 lung cancer data and an FDA-approved Phase 3 protocol amendment that could accelerate the registration process.
- A successful global offering has significantly bolstered the company's balance sheet, extending its cash runway through 2029 and supporting long-term sentiment.